Aurinia Pharmaceuticals (AUPH) Net Equity Issued and Repurchased (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $355000.0 in Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 6.82% year-over-year to $355000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $736000.0 (down 99.63% YoY) and the FY2025 annual result came in at $756000.0, down 30.26% from the prior year.
• Net Equity Issued and Repurchased retreated to $355000.0 in Q4 2025, from $381000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $196.7 million in Q4 2021 to a low of $355000.0 in Q4 2025.
• A 3-year average of $65.8 million and a median of $381000.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 6.82% in 2025, down 6.82% in 2025.
• Tracing AUPH's Net Equity Issued and Repurchased over 3 years: stood at $196.7 million in 2021, then slumped by 99.81% to $381000.0 in 2024, then retreated by 6.82% to $355000.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $355000.0 (Q4 2025), $381000.0 (Q4 2024), and $196.7 million (Q4 2021), per Business Quant data.